Viewing Study NCT05222932

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:27 PM
Ignite Modification Date: 2026-02-01 @ 7:53 PM
Study NCT ID: NCT05222932
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-07
First Post: 2022-02-01
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Sponsor: TILT Biotherapeutics Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
None Head and Neck Squamous Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None oncolytic virus View
None immunotherapy View
None immune checkpoint inhibitor View